With this technology, early screening and dynamic monitoring of CRC can be achieved through combined detection of circulating tumor DNA (ctDNA) and carcinoembryonic antigen (CEA) [10,11,12,13,14,15,16,17,18,19]. This evidence concerns the gene CEACAM5 and neoplasm.